Quote:

---

"Patients completing study CD-O-101 will be given the option to enter a roll-
over study where they can continue to receive leronlimab.

---

This allows patients who respond to leronlimab to continue receiving treatment after the study is completed. Without the rollover, the patient would automatically stop receiving the drug. This would be cruel. It might also hinder trial enrollment.

Quote:

---

Patients who
have progressed on the parent study will also be offered treatment with
leronlimab in combination with an immune checkpoint inhibitor.

---

The primary endpoint of the study is ORR. Once the patient has progressed, they have gone beyond their best response. Therefore, they will then be offered ICI if PDL-1 levels warrant. To withhold it for an arbitrary 48 weeks would be meanigless and unethical. Besides, the patient would simply drop from the study and seek the ICI.

I interpret Hoffman's "throughout the study" comment to mean he hopes LL raises PDL-1 levels in all patients participating in the study as opposed to the duration of the study.